StemCells, Inc. Interim Results Show Improvement in Visual Function and Slowing of Disease Progression in Phase I/II Dry AMD Trial
Company to Host Webcast to Discuss Interim Data Today
NEWARK, Calif., June 19, 2014 -- StemCells, Inc. (STEM) reported positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SC(R) human neural stem cell platform in dry age-related macular degeneration (AMD) yesterday evening at the 12th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada.
- Interim trial results show a 65 percent reduction in the rate of geographic atrophy (GA) in the study eye when compared to the expected natural history of the disease as well as a 70 percent reduction in the rate of GA when compared to the control eye.
- Published: 19 June 2014
- Written by Editor